Bosutinib (BOS) vs imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial Meeting Abstract
| Authors: | Cortes, J.; Gambacorti-Passerini, C.; Deininger, M.; Mauro, M.; Chuah, C.; Kim, D. W.; Reilly, L.; Jeynes-Ellis, A.; Leip, E.; Bardy-Bouxin, N.; Hochhaus, A.; Brümmendorf, T. |
| Abstract Title: | Bosutinib (BOS) vs imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial |
| Meeting Title: | 5th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 17 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Sep 13-16 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-09-01 |
| Start Page: | S316 |
| Language: | English |
| ACCESSION: | 124936107 |
| DOI: | 10.1016/j.clml.2017.07.117 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abstract: CML-168 -- Accession Number: 124936107 -- Entry Date: In Process -- Revision Date: 20170904 -- Publication Type: Article -- Supplement Title: Sep2017 Supplement 2 -- Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101525386. -- Source: cin20 |
